PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Traffic. Author manuscript; available in PMC Dec 1, 2010.
Published in final edited form as:
PMCID: PMC2783697
NIHMSID: NIHMS139273
Endocytosis and Intracellular Trafficking of Human Natural Killer Cell Receptors
Madhan Masilamani,1 Giovanna Peruzzi,2* Francisco Borrego,3# and John E. Coligan2,4
1The Jaffe Food Allergy Institute, Department of Pediatrics, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
2Receptor Cell Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health,Rockville, MD 20852, USA
3Laboratory of Molecular and Developmental Immunology, Division of Monoclonal Antibodies, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
4Address Correspondence: Dr. John E. Coligan, Receptor Cell Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II, Room 205, 12441 Parklawn Drive, Rockville, MD 20852, USA, jcoligan/at/niaid.nih.gov
*Co-first author
#Co-senior author
Natural killer (NK) cells play a vital role in the defense against viral infections and tumor development. NK cell function is primarily regulated by the sum of signals from a broad array of activation and inhibitory receptors. Key to generating the input level of either activating or inhibitory signals is the maintenance of receptor expression levels on the cell surface. Although the mechanisms of endocytosis and trafficking for some cell surface receptors, such as transferrin receptor, and certain immune receptors, are very well known, that is not the situation for receptors expressed by NK cells. Recent studies have uncovered that endocytosis and trafficking routes characteristic for specific activation and inhibitory receptors can regulate the functional responses of NK cells. In this review, we summarize the current knowledge of receptor endocytosis and trafficking, and integrate this with our current understanding of NK cell receptor trafficking.
There is a large amount of literature regarding the endocytosis and trafficking of membrane receptors. Some of these studies have focused on immune receptors. With the exception of major histocompatibily complex (MHC) molecules, most immune receptors that have been analyzed are “activation” receptors and their downregulation after ligation often serves to regulate the immune response. For example, it has been shown that the T cell receptor (TCR) is constitutively recycled in resting T cells and that the ligation of TCR enhances endocytosis and degradation, which serves to control excessive inflammation (13). B lymphocytes function as efficient antigen presenting cells mainly through presentation of antigens internalized via the B cell receptor (BCR) (4). The ligation of cell surface receptors usually initiates a signaling process. The signaling process can continue after internalization as the receptors traffic through the endocytic compartments (57). The trafficking and endocytosis of some immune receptors, such as Toll–like receptors (TLRs) (8) Fc Receptors (911) and MHC molecules (1214), have also received significant attention; however, only a few studies have focused on receptor trafficking in natural killer (NK) cells.
Endocytosis and intracellular trafficking
Here, we briefly summarize the various mechanisms known to be involved in receptor mediated endocytosis. Endocytosis is the process by which cells uptake molecules from the extracellular environment. This process is historically divided into two broad types: phagocytosis, which involves ingestion of large particles, such as bacteria and dead cells, and pinocytosis, a process associated with fluid phase uptake. The pinocytic uptake of solutes can be receptor-mediated (e.g. clathrin mediated) or non-specific in nature such as in macro or micropinocytosis (15).
Many cell surface proteins that are internalized into endosomal vesicles by non-phagocytic means utilize the well-characterized clathrin-mediated endocytic (CME) pathway (1517). Others utilize less defined routes that are mostly categorized as caveolin-dependent, lipid raft-dependent, or macropinocytosis (1820). One should realize, however, that it is not always easy to draw clear distinctions among these pathways (21) and that some receptors, depending on the circumstances, are not necessarily restricted to a single endocytic pathway (2224). CME requires the formation of clathrin triskelion and concerted action of adaptor proteins (such as AP2, EPS-15 etc) to form clathrin coated buds at the cell surface (2527). The clathrin coated vesicles pinch off the cell membrane through the action of dynamin (17). The internalization mechanisms of non-clathrin-dependent pathways are less well characterized (18, 19, 28). A major clathrin-independent pathway is thought to be mediated by caveolae, but the role of caveolae in immune cells remains controversial. Even though the characteristic caveolae-like structures are absent in lymphocytes (29, 30), the expression of caveolin-1, the essential component of caveolae has been reported in immune cells (3134). Some receptors appear to rely at least partially on a little understood mechanism that is lipid raft-mediated. This includes such important immune system receptors as TCR (13), BCR (35), the high affinity receptor for IgE (FcεRI) (36) and the interleukin (IL)-2 receptor (37, 38). Receptor endocytosis is currently considered as lipid raft- dependent if internalized vesicles co-localize with proteins known to be lipid raft associated (for example, flotillins and GM1 gangliosides (39)), are endocytosed by a mechanism independent of clathrin-associated machinery (40) and the internalized proteins reside in the detergent resistant membrane (DRM) fraction (36).
As stated previously, some receptors can utilize several alternative pathways for internalization and trafficking depending on the circumstances (2224). For example, BCR is internalized via both CME and clathrin-independent lipid raft associated pathways (35, 41). FcεRI has been reported to undergo endocytosis by both CME and clathrin-independent pathways (36, 42). CME is the major pathway of epidermal growth factor receptor (EGFR) internalization; however, it can also be internalized via a clathrin-independent mechanism with different outcomes. EGFR internalized via CME is not targeted for degradation, but instead recycled back to the cell surface. On the other hand, EGFR internalized by clathrin-independent route is preferentially targeted for degradation (23). Transforming growth factor (TGF)-β receptor can also be internalized by CME or a clathrin-independent/lipid raft endocytic pathway (22, 43). In the case of CD317, clathrin- and lipid raft-mediated endocytic processes act in concert to mediate efficient endocytosis (44). Endocytic routes are often determined by structural motifs in the cytoplasmic portion of cell surface receptors (25, 45). For example, it has been shown that ligation promotes phosphorylation of the Tyr in the ITAM motifs of a subset of BCR that are selectively retained at the cell surface to serve as scaffolds for the assembly of signaling molecules. In contrast, the non-phosphorylated receptors are rapidly endocytosed (46).
Several internalization pathways, including clathrin- dependent and -independent mechanisms, share the requirement for dynamin (15, 36, 37, 47) and Arf6. Dynamins are large GTPases (MW ~100 kDa) responsible for fission of newly formed endocytic vesicles from the cell membrane (15, 48). The GTP hydrolysis provides the force required for membrane budding events at the neck of the nascent endocytic vesicle (49). Development of mutant dynamin constructs (50, 51) and dynamin specific inhibitors such as dynasore (52) have helped determine the requirement for dynamin involvement in endocytic pathways.
Arf6 is a small GTPase, implicated in various cellular events such as cell adhesion, structural organization at the cell membrane, endocytosis, macropinocytosis and phagocytosis (53). Arf6 has been shown to regulate both clathrin-dependent and -independent endocytic pathways (54). MHC class I molecules are endocytosed via a clathrin independent, Arf6 mediated pathway (14, 55). Other plasma membrane proteins such as α1 integrins, M2-muscaranic acetylcholine receptors and the peripheral myelin-membrane protein are also internalized by Arf6 mediated pathways (54). In addition, Arf6 is known to be required for endosomal recycling of IL-2 receptor alpha subunit, GPI-anchored proteins and MHC class I molecules (56, 57) and for induction of membrane protrusions and uptake of plasma membrane proteins into macropinosomes (58).
Macropinocytosis is a specialized form of endocytosis, whereby extracellular fluid is engulfed forming large endocytic vesicles called macropinosomes (5962). Although there are no specific cargoes or markers that define this endocytic mechanism, sensitivity to inhibitors of Na+/H+ exchange, such as amiloride, and enhanced fluid-phase uptake in response to growth factor stimulation are used to discriminate this mechanism (6264). Co-endocytosis of fluid phase markers such as lucifer yellow and dextran into large vesicles (0.5–5 µm) allows the tracing of macropinosomes in cells. Macropinocytosis is associated with plasma membrane ruffling mediated by Ras superfamily GTPases (65, 66). Phorbol esters stimulate macropinocytosis by inducing membrane ruffles via protein kinase C and Rac (67, 68). The formation of macropinocytic vesicles has been shown to involve actin polymerization (64, 69), dynamin (70, 71), phosphoinositide 3-kinase (PI3K) (72) and small GTPases, such as Arf6 (54, 73), Cdc42 and Rac1 (74). The GTPase function of Cdc42 is thought to be essential for macropinocytosis in dendritic cells (DC) (66). However, none of these biochemical characteristics in itself can be considered a hallmark for macropinocytosis. For example, amiloride does not specifically inhibit macropinocytosis in DC (75) and, ICAM-1 and PECAM-1 internalization, which is known to involve macropinocytosis does not require PI3K (70). The macropinosomes mature intra-cellularly by fusing with endosomes and later with lysosomes (59, 62, 76). Aquaporins (AQP), the membrane water channel proteins, have been shown to play an important role in controlling the cellular volume during macropinocytosis in immature DC (77). Along with amiloride sensitive Na+/H+ channels, AQP3 and AQP7 facilitate concentration of macromolecules and efficient antigen presentation.
Micropinocytosis is the process of non-specific, constitutive uptake of extracellular molecules by the formation of small vesicles from the plasma membrane in the absence of activation or membrane ruffles (61). Micropinocytosis is morphologically distinguishable from macropinocytosis by the size of the pinosome, i.e., lesser than 0.2 µm. In addition, micropinocytosis is not dependent on actin cytoskeleton and PI3K (78, 79). Recently, dynamin 2 has been shown to mediate micropinocytosis in epithelial cells (80).
Ubiquitination is a post-translational and reversible modification in which the small (76-residue) protein ubiquitin (Ub) is attached to a substrate protein. This modification has been shown to be involved in the endocytosis and intracellular trafficking of cell surface receptors (81, 82). This modification occurs through a multi-step process that requires the action of a hierarchical set of enzymes (E1, E2 and E3) leading to the linkage of Ub to the ε-amino group of lysine residues in the acceptor protein (83). Receptors can be mono-, multi-mono-, or polyubiquitinated. The addition of a single molecule of Ub to a single Lys residue in the target protein (monoubiquitination) or the addition of single Ub to different residues (multiubiquitination), among other things, can dictate endocytic fates (84). The Ub itself has seven different Lys residues that can be used to form chains of polyubiquitin. The formation of Lys-48 polyubiquitin chains is known to target proteins for degradation in the 26S–proteasome (85). Lys-63 linked polyubiquitinated chains is known to involved in receptor endocytosis and signaling, as in the case of EGFR (86) and the lysosomal degradation of major histocompatibility complex (MHC) class I molecules (87). Additional studies on ubiquitination of EGFR (86, 88), TGFβR (22) and FcεRI (89) underline the role of ubiquitination in determining receptor endocytosis and trafficking.
Once internalized, the receptor-ligand complexes enter early endosomes (90, 91). The classical early endosomal compartment is defined by the presence of early endosomal antigen (EEA)1. Recent studies indicate that early endosomes are a more heterogeneous than previously believed and that they possess distinct membrane domains (9295). Two distinct populations of early endosomes have been discovered, one that is highly dynamic and rapidly maturing and another that is static and mature much more slowly (95). Subsequent maturation of endosomes is regulated by recruitment of Rab GTPases. Membrane domains of endosomes contain a mosaic of different Rab proteins (96, 97). Many molecular switches are likely involved in the transition between endosomal compartments (98, 99). From the early endosomes, the cargo that is recycled to plasma membrane are sequentially transported from Rab5 to Rab4 and Rab11 domains, the cargo destined for degradation are transported from Rab5 to Rab7 domains (93, 96, 100). Consequently, GFP-tagged Rab proteins can be used to identify endosomal compartments. Rab5 and Rab4 identify distinct domains of early sorting endosomes; Rab4 is associated with regions in the early endosomes destined for fast recycling to the plasma membrane. Recycling endosomes are characterized by the presence of Rab11, whereas Rab7 is the key determinants for the late endosomes. Cargos from late endosomes are subsequently targeted to lysosomes for degradation (93, 96).
Endocytic pathways of NK cell receptors
NK cells are large granular lymphocytes that play an important role in the defense against viral infections and tumorigenesis through the production of cytokines and cytotoxicity. NK cell functions are regulated by the expression of a broad number of activating and inhibitory receptors. During NK cell-target cell interactions, whether NK cells are activated or not depend on the balance of the signals emanating from these receptors (101). The NK cell activation receptors represent a family of heterogeneous molecules, including NKG2D, CD16, 2B4 and members of natural cytotoxicity receptors (NCR), NKp30, NKp44 and NKp46 among others (102). CD94/NKG2A, members of killer cell immunoglobulin-like receptor (KIR) family and immunoglobulin-like transcripts (ILT) are important inhibitory receptors expressed by NK cells (101, 103, 104). These inhibitory receptors bind to MHC class I molecules on normal cells and prevent excessive NK cell activation resulting in untoward cytotoxicity and inflammation (104). Other inhibitory receptors expressed on NK cells, although on other immune cells as well, include LAIR-1 (105107), CD300a (108) and KLRG1 (109). For a more complete list of NK cell receptors see the recent review of Biassoni (102).
NKG2D
NKG2D belongs to the C-type lectin protein family and was once thought to act as an activation receptor for NK cells and costimulatory receptor for T cells, but more recent evidence indicates that it may also be co-stimulatory for NK cells (110, 111). NKG2D plays a major role in immunity against tumors and pathogens (112). Human NKG2D has several ligands, including MHC class I-chain related proteins (MIC)-A and MIC-B and UL16-binding protein (ULBP). These ligands are usually upregulated when normal cells are transformed, subjected to stress or infected (112). Ligand binding to human NKG2D induces activation signals through the associated DAP10, resulting in cytotoxicity towards the susceptible target cells and/or secretion of inflammatory cytokines (112).
Soluble and membrane bound ligands can lead to NKG2D downmodulation, which promotes tumor evasion (112116). Colorectal cancer patients have abnormally higher levels of soluble MIC-A and –B in circulation. Interestingly, incubation of NK cells from these patients with autologous serum that contains soluble MIC-A and –B, not only resulted in downregulation of NKG2D, but also of the activation receptor NKp44 (113). Moreover, internalization of the chemokine receptors CXCR1 and CCR7 was also observed. The secondary downregulation of NKp44, CXCR1 and CCR7 seems to be dependent on NKG2D downmodulation, although how this occurs is not obvious. Antibody induced internalization of NKG2D in NK cells involves the actin cytoskeleton, as disruption of actin polymerization impairs the rate of endocytosis (21). As on NK cells, tumor-derived NKG2D ligands impair expression of NKG2D and its activation on CD8+ T cells (115). Groh et al. showed that the total amount of human NKG2D on CD8+ T cells was decreased after contact with ligand expressing target cells, as a consequence of lysosomal degradation (as shown by treating cells with the two inhibitors of lysosomal degradation bafilomycin A and chloroquine) (115). NKG2D expressed by murine NK cells is also downregulated when exposed to ligand (RAE-1ε) (114). This downregulation was sensitive to hypertonic medium suggesting that it is clathrin-mediated. Although there was no direct evidence of the adaptor protein AP2 binding to DAP10 YXXM motif, the motif is required for ligand-induced endocytosis, as is PI3K activation (114). [The cytoplasmic YXXΦ motif (Φ, a bulky hydrophobic amino acid) of several membrane receptors serves as a docking site for AP2 (25, 45)].
Roda-Navarro and Reyburn (117) have found that in resting human NK cells NKG2D resides primarily on the cell surface, while in cytokine activated NK cells, an intracellular pool of receptor can also be found that cycles to the plasma membrane (117). They also observed that exposure of NK cells to MIC-B expressing target cells resulted in degradation of NKG2D and DAP10 in the lysosomes (as indicated both by treatment with chloroquine and confocal microscopy observations). In contrast, for murine NKG2D, Ogasawara et al. reported that for Ba/F3 cells expressing mouse NKG2D and DAP10, the cell surface expression of NKG2D was reduced after interaction with RAE-1γ expressing RMA cells, but this downmodulation did not affect the total cellular NKG2D, suggesting that the internalized NKG2D was not degraded (114). The reasons for the discrepancies between studies are not known but differences between mouse and human NKG2D receptors and the cells expressing NKG2D, i.e., primary cells vs transfectants, need to be considered.
NKp46
NKp46 is expressed on the surface of both activated and resting NK cells (118). Viral encoded ligands for NKp46 have been identified (119, 120), but the tumor ligands still remain unknown. Sivori et al, showed that incubation of human NK cell clones with immobilized anti-NKp46 antibody resulted in the downregulation of NKp46 from the cell surface (121). NKp46 downmodulation induced by incubation with the tumor cell line 721.221 was not blocked by the ligation of inhibitory receptors (122). Unexpectedly, NKp46 expression is decreased when NK cells are treated with the proteasome inhibitor bortezomib (123). To explain this apparent contradiction, these investigators suggested that the decreased levels of NKp46 may be, at least in part, is attributable to the known inhibitory effects of bortezomib on NF-κB function. In fact, treatment of NK cells with a selective pharmacological inhibitor of NF-κB substantially decreased NKp46 cell surface levels (123).
CD16
CD16, also known as the low affinity receptor for IgG (FcγRIIIa), is the receptor responsible for the induction of the NK antibody-dependent cellular cytotoxicity (ADCC) (124). CD16, expressed by most NK cells, is able to transduce an activating signal through its association with CD3ζ and FcεRIγ chains (125, 126). Upon CD16 cross-linking using specific mAb, the receptor is rapidly internalized by an ATP independent mechanism that requires an intact actin cytoskeleton (127). Others have shown that specific mAb mediated downregulation of CD16 is blocked by the Zn2+-dependent metalloproteases inhibitor, 1,10-phenanthroline, suggesting that the downregulation of CD16 from the cell surface is more a consequence of metalloprotease induced shedding of receptor rather than internalization (128). Shedding of CD16 has also been shown after treatment of NK cells with the PKC activator PMA (128, 129). Additional studies are required to determine the contribution of internalization and shedding to the mAb mediated downregulation of CD16. It has been shown that the phosphatidylcholine-specific phospholipase C (PC-PLC) is associated with CD16 in lipid rafts and is involved in the regulation of CD16 membrane expression, as a specific inhibitor of PC-PLC strongly down-modulates CD16 expression (127). The CD16 CD3ζ subunit is rapidly ubiquitinated by lck after aggregation of CD16, probably directing this subunit to degradation (130).
2B4 (CD244)
2B4 is one of the three members of the signaling lymphocytic activating molecule (SLAM) family receptors expressed by NK cells that has been shown to have both activation and inhibitory potential (131137). 2B4 crosslinking with mAb or incubation with target cells expressing its ligand CD48 induces downregulation from the cell surface by internalization. Inhibitory receptors do not block ligand induced 2B4 downmodulation. 2B4 internalization requires Src kinases, although it has been suggested that the internalization is independent of PI3K activity or actin polymerization (122). Other examples of receptors belonging to the SLAM family that are downregulated upon ligand binding are: SLAM (CD150) (138) and CD229 (LY9) (139). However, another member of this family, NTB-A was not down-regulated after culturing NK cells with NTB-A expressing cell lines [NTB-A exhibits homophilic binding (122)]. Within the SLAM family, CD229 (Ly9) is the only member that binds to the μ2 chain of the AP-2 complex (139).
CD94/NKG2A
CD94/NKG2A is an inhibitory receptor of the C-type lectin family found in humans and mice, which binds to the non-classical class I molecule HLA-E (140142). Ligation of the receptor with HLA-E promotes phosphorylation of the Tyr in the cytoplasmic ITIM domain of CD94/NKG2A leading to the recruitment and activation of src homology 2 domain-bearing tyrosine phosphatase (SHP)-1 and/or SHP-2 (143145). SHP-1 activation results in dephosphorylation of Vav and ezrin/radixin/moesin (ERM) proteins leading to the actin depolymerization and disruption of the cytoskeleton. As a consequence, lipid rafts and activating receptors are excluded at the site of contact between NK cell and target cell, negating the propagation of positive signals (146148).
The investigation of CD94/NKG2A endocytosis and trafficking revealed some surprising results (21, 149). CD94/NKG2A continuously recycles between the cell surface and intracellular compartments in a process that is independent of inhibitory signaling (149). Endocytosis of CD94/NKG2A resembles classical macropinocytosis in that it is independent of clathrin, lipid rafts and PI3K activity, requires Rac1, and is sensitive to amiloride. It differs from classical macropinocytosis by not requiring actin, dynamin or Arf6. Actin polymerization is required for the recycling of CD94/NKG2A back to the cell surface (21). Once endocytosed, CD94/NKG2A localizes in the early endosomal compartment, as demonstrated by co-localization with EEA1 and Rab5, and recycles back to the cell surface.
CD94/NKG2C
CD94/NKG2C is a DAP12 associated activation receptor closely related to CD94/NKG2A (103). The extracellular region of NKG2C is 92% identical to NKG2A and the receptor also recognizes HLA-E (albeit with lower affinity) (103, 150). Using a mouse cell line Ba/F3 transfected with CD94/NKG2C/DAP12, we have shown that CD94/NKG2C is a long-lived receptor that differs in its trafficking route from CD94/NKG2A (149). Like transferrin receptor, the cell surface levels of CD94/NKG2C/DAP12 are decreased after brefeldin A treatment, suggesting that CD94/NKG2C/DAP12 traffics through brefeldin A sensitive intra-cellular trafficking compartments. Brefeldin A is known to cause tubulation and fusion of early endosomes with the trans-Golgi network thereby blocking recycling, as shown for the transferrin receptor, and to obstruct anterograde transport from the endoplasmic reticulum to the Golgi complex (151, 152).
Killer cell immunoglobulin-like receptors (KIR)
KIR comprise a group of polymorphic molecules that consist of both activation and inhibitory receptors that are expressed on NK cells and a subset of T lymphocytes (153). Individual KIR bind to MHC HLA-A, -B or -C class I molecules. KIR have two (KIR2D) or three (KIR3D) immunoglobulin domains in the extracellular portion of the molecule. The inhibitory KIR have a long cytoplasmic tail (KIR2DL and KIR3DL) that contain ITIM sequences, while the activating KIR contain a short cytoplasmic tail (KIR2DS and KIR3DS) that lack ITIMs but contain lysine in the transmembrane portion. The positively charged amino acid is required for pairing with the ITAM containing adaptor molecule DAP12, which is required for signaling (154). An exception to this general classification is KIR2DL4. KIR2DL4 has a transmembrane arginine and one ITIM in the intracellular domain. Ligation of this receptor with mAbs or with its ligand HLA-G has shown that it has mostly activating function. This is manifested by the potent production of IFN-γ, as well as of other cytokines, and weak cytotoxic activity (155157). The activating functions of KIR2DL4 depend on the transmembrane association with the adaptor molecule FcεRIγ instead of DAP12 (158); however, it has also been shown that some KIR2DL4 mediated activation signals are independent of the association with FcεRIγ (159).
On CD8+ T cells, in the absence of TCR stimulation, engagement of KIR2DL with the ligand HLA-Cw7 induces downregulation of KIR2DL. The internalized KIR2DL is routed to lysosomes and degraded. When TCR is stimulated with appropriate antigen, the KIR2DL downregulation is inhibited and stable cell surface levels of KIR2DL are maintained, likely serving to elevate the activation threshold of cytotoxic T cells to avoid excessive stimulation leading hyper inflammation (160). For NK cells conflicting results have been reported. Huard et al. have shown that KIR2DL2 is downregulated after incubation of NK cell clones with target cells bearing the appropriate ligand (161). As on T cells, this downregulation showed a slow kinetics and, more importantly, was associated with the downregulation of other activating receptors, such as CD16, rendering the NK cells unresponsive to activating signals (161). However, others have shown that crosslinking of a cell line transfected with KIR2DL1 with specific mAb antibodies did not induce downmodulation of the receptor (122). It is possible that the different experimental settings may explain these conflicting results. In any case, more detailed studies in more physiological settings are required to study the fate of KIRs after interaction with their ligands.
A role for PKCδ in controlling expression of KIR has been proposed. Chwae et al. have used a panel of Jurkat T cells transfected with different constructs expressing wild type and mutant forms of KIR, as well as chimeric fusion receptors composed of the extracellular and transmembrane part of CD8α and the intracellular tail of KIR3DL1 (162, 163). They have shown that PKCδ activation upregulates membrane expression of KIR. This upregulation is associated with increased processing in the ER-Golgi and also increased recycling of KIR via EEA1+ endosomes. They also showed, using pharmacological inhibitors, that PKCδ plays a role in the exocytosis of KIR from secretory lysosomes. Others have shown that phosphorylation of a specific Ser residue (Ser394) in the cytoplasmic tail of KIR3DL1 inhibits the inhibitory function of this receptor, as well as its internalization and turnover (164).
KIR2DL4 binds soluble HLA-G and is endocytosed into Rab5+ endosomes in a dynamin-dependent process. The result of this internalization is the secretion of inflammatory and angiogenic factors, such as TNF-α, IL-1β, IL-8 and IFN-γ (156). As the expression of HLA-G is restricted to trophoblast cells that invade maternal deciduas during early pregnancy, these findings suggest that interaction of KIR2DL4 with HLA-G promotes vascularization of the maternal decidua (156). The KIR2DL4 activation signaling has been proposed to occur in the endosomes, as only soluble but not membrane-bound or plate-bound antibodies to KIR2DL4 induced IFN-γ secretion. However, it has also been shown that uterine NK cells can be stimulated not only by soluble HLA-G, but also by membrane bound HLA-G. Co-incubation of uterine NK cells with cell lines transfected with membrane bound HLA-G leads to proliferation and IFN-γ production (165).
Our current understanding of the role of receptor trafficking in regulating NK cell function
Receptor downregulation upon ligand binding is a well documented means for modulating receptor signaling (1, 90, 160, 161). As shown for the TCR (1), this downregulation serves to dampen the intensity and duration of a cell’s response as means of regulating the overall response. Most if not all of the NK cell activation receptors studied have been shown to be downregulated upon ligand binding (112, 121, 122). After ligand-induced downmodulation, the default intracellular trafficking pathway seems to lead to lysosomes for degradation (90). By limiting the availability of activation receptors by downmodulation from the cell surface, the cells not only become refractory to more stimulation, but may also prevent cell death associated with sustained activation (activation induced cell death) (166, 167). However, it is not yet clear if signaling from NK cell activation receptors continues in endocytic compartments.
As for inhibitory receptors, there is a requirement that they be continuously expressed on the NK cell surface to prevent undesirable activation. The primary NK cell inhibitory receptors, CD94/NKG2A and inhibitory KIRs, responsible for recognition of self MHC class I molecules, are constantly exposed to ligand expressed by surrounding cells. It could be potentially disastrous for these receptors to be downregulated, as the balance of signals could then tip toward activation leading to auto-reactive NK cells, as many ligands for NK cell activation receptors are expressed by normal cells. In order to restrain this unwanted activation of NK cells, it would be desirable for these inhibitory receptors to remain in constant supply at the cell surface. This could be achieved by new synthesis, rapid recycling or a combination of both. It would seem advantageous for inhibitory receptor trafficking to be designed in such a way to insure this continuous supply at the cell membrane. From an energetic point of view, it would be beneficial for the cell to achieve this by quickly directing the internalized receptors from early endosomal compartments back to the cell membrane rather than rely on de novo protein synthesis. In this light, our studies on human CD94/NKG2A have shown that cell surface expression levels are maintained in the face of ligand exposure and that the receptors are long lived and, upon endocytosis, rapidly recycle to the cell surface using an abbreviated trafficking pattern (21, 149). Current data indicates that all NK cell inhibitory receptors do not share this trafficking scheme as KIR inhibitory receptors may be downregulated by ligand exposure under certain experimental conditions (see above). At this moment, it is not clear if these differing results for CD94/NKG2A and KIR are due to the different experimental settings or something else. Clearly, more experiments are warranted to address endocytosis and trafficking of inhibitory receptors in situations that reflect physiological conditions.
A curious aspect of CD94/NKG2A trafficking is that its endocytosis is apparently actin-independent. The actin cytoskeleton is absolutely essential for NK cytotoxicity (168) and is shown to be a target for inhibitory signaling (147, 169, 170). The actin cytoskeleton also provides the scaffold for the formation of the signalosome, a multi-molecular assembly that is formed by aggregation of pre-assembled lipid raft platforms and it plays a major role in regulating the endocytosis of cell surface proteins from these signalosomes. The actin cytoskeleton is known to be involved in most internalization processes including macropinocytosis (64, 171, 172). Interestingly, the engagement of CD94/NKG2A, as well as inhibitory KIR, on NK cells disrupts actin reorganization (147, 170, 173). So, perhaps it is not surprising that the endocytosis of CD94/NKG2A apparently does not depend on actin polymerization. CD94/NKG2A does, however, require actin for de novo and recycling protein trafficking to the cell surface (21). It is possible that by-passing the requirement of actin allows CD94/NKG2A to quickly internalize and recycle to a different location within a short period of time, thereby, maintaining inhibitory receptor presence on the cell surface.
In the complex scenario of receptor endocytosis and intracellular trafficking, much has been learned, but much more needs to be explored. Particularly, much less in known about NK cell receptor endocytosis and trafficking. We have to be aware of the multiplicity of scenarios, such as cell type, environment, ligand conditions, that can alter a receptors trip through the cell, perhaps, in some cases, affecting cell function. In particular, for immune system receptors, such as those on NK cells, a deeper understanding of the factors regulating trafficking could potentiate the development of drugs or other means for controlling receptor surface expression that would have therapeutic value. A good example of this might be having the ability to maintain NKG2D expression in the face of ligand exposure.
Acknowledgements
This work is supported by funds from the Division of Intramural Research, NIAID/NIH to JEC, Intramural program, FDA to FB and by The Jaffe Food Allergy Institute, Mount Sinai School of Medicine to MM. We would like to thank Dr. Konrad Krzewski for his critical reading of the review.
Footnotes
Disclosures
The authors have no financial conflicts of interest.
1. Alcover A, Alarcon B. Internalization and intracellular fate of TCR-CD3 complexes. Crit Rev Immunol. 2000;20(4):325–346. [PubMed]
2. Geisler C. TCR trafficking in resting and stimulated T cells. Crit Rev Immunol. 2004;24(1):67–86. [PubMed]
3. Barr VA, Balagopalan L, Barda-Saad M, Polishchuk R, Boukari H, Bunnell SC, Bernot KM, Toda Y, Nossal R, Samelson LE. T-cell antigen receptor-induced signaling complexes: internalization via a cholesterol-dependent endocytic pathway. Traffic. 2006;7(9):1143–1162. [PubMed]
4. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol. 2005;238(2):67–75. [PubMed]
5. von Zastrow M, Sorkin A. Signaling on the endocytic pathway. Curr Opin Cell Biol. 2007;19(4):436–445. [PMC free article] [PubMed]
6. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol. 2004;16(4):400–406. [PubMed]
7. McPherson PS, Kay BK, Hussain NK. Signaling on the endocytic pathway. Traffic. 2001;2(6):375–384. [PubMed]
8. Watts C, Zaru R, Prescott AR, Wallin RP, West MA. Proximal effects of Toll-like receptor activation in dendritic cells. Curr Opin Immunol. 2007;19(1):73–78. [PubMed]
9. Swanson JA. Shaping cups into phagosomes and macropinosomes. Nat Rev Mol Cell Biol. 2008;9(8):639–649. [PMC free article] [PubMed]
10. Swanson JA, Hoppe AD. The coordination of signaling during Fc receptor-mediated phagocytosis. J Leukoc Biol. 2004;76(6):1093–1103. [PubMed]
11. Amigorena S, Bonnerot CFc. receptor signaling and trafficking: a connection for antigen processing. Immunol Rev. 1999;172:279–284. [PubMed]
12. Caplan S, Naslavsky N, Hartnell LM, Lodge R, Polishchuk RS, Donaldson JG, Bonifacino JS. A tubular EHD1-containing compartment involved in the recycling of major histocompatibility complex class I molecules to the plasma membrane. EMBO J. 2002;21(11):2557–2567. [PubMed]
13. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8(8):607–618. [PMC free article] [PubMed]
14. Naslavsky N, Weigert R, Donaldson JG. Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements. Mol Biol Cell. 2004;15(8):3542–3552. [PMC free article] [PubMed]
15. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37–44. [PubMed]
16. Doherty GJ, McMahon HT. Mechanisms of Endocytosis. Annu Rev Biochem. 2009 [PubMed]
17. Rappoport JZ. Focusing on clathrin-mediated endocytosis. Biochem J. 2008;412(3):415–423. [PubMed]
18. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007;8(8):603–612. [PubMed]
19. Kirkham M, Parton RG. Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta. 2005;1746(3):349–363. [PubMed]
20. Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6(2):112–126. [PubMed]
21. Masilamani M, Narayanan S, Prieto M, Borrego F, Coligan JE. Uncommon endocytic and trafficking pathway of the natural killer cell CD94/NKG2A inhibitory receptor. Traffic. 2008;9(6):1019–1034. [PubMed]
22. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 2003;5(5):410–421. [PubMed]
23. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 2008;15(2):209–219. [PubMed]
24. Benmerah A, Lamaze C. Clathrin-coated pits: vive la difference? Traffic. 2007;8(8):970–982. [PubMed]
25. Brodsky FM, Chen CY, Knuehl C, Towler MC, Wakeham DE. Biological basket weaving: formation and function of clathrin-coated vesicles. Annu Rev Cell Dev Biol. 2001;17:517–568. [PubMed]
26. Sorkin A. Cargo recognition during clathrin-mediated endocytosis: a team effort. Curr Opin Cell Biol. 2004;16(4):392–399. [PubMed]
27. Schmid EM, McMahon HT. Integrating molecular and network biology to decode endocytosis. Nature. 2007;448(7156):883–888. [PubMed]
28. Donaldson JG, Porat-Shliom N, Cohen LA. Clathrin-independent endocytosis: a unique platform for cell signaling and PM remodeling. Cell Signal. 2009;21(1):1–6. [PMC free article] [PubMed]
29. Sengelov H, Voldstedlund M, Vinten J, Borregaard N. Human neutrophils are devoid of the integral membrane protein caveolin. J Leukoc Biol. 1998;63(5):563–566. [PubMed]
30. Fra AM, Williamson E, Simons K, Parton RG. Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae. J Biol Chem. 1994;269(49):30745–30748. [PubMed]
31. Kiss AL, Turi A, Mullner N, Timar J. Caveolin isoforms in resident and elicited rat peritoneal macrophages. Eur J Cell Biol. 2000;79(5):343–349. [PubMed]
32. Lei MG, Morrison DC. Differential expression of caveolin-1 in lipopolysaccharide-activated murine macrophages. Infect Immun. 2000;68(9):5084–5089. [PMC free article] [PubMed]
33. Gargalovic P, Dory L. Caveolin-1, and caveolin-2 expression in mouse macrophages. High density lipoprotein 3-stimulated secretion and a lack of significant subcellular co-localization. J Biol Chem. 2001;276(28):26164–26170. [PubMed]
34. Medina FA, Williams TM, Sotgia F, Tanowitz HB, Lisanti MP. A novel role for caveolin-1 in B lymphocyte function and the development of thymus-independent immune responses. Cell Cycle. 2006;5(16):1865–1871. [PubMed]
35. Stoddart A, Jackson AP, Brodsky FM. Plasticity of B cell receptor internalization upon conditional depletion of clathrin. Mol Biol Cell. 2005;16(5):2339–2348. [PMC free article] [PubMed]
36. Fattakhova G, Masilamani M, Borrego F, Gilfillan AM, Metcalfe DD, Coligan JE. The high-affinity immunoglobulin-E receptor (FcepsilonRI) is endocytosed by an AP-2/clathrin-independent, dynamin-dependent mechanism. Traffic. 2006;7(6):673–685. [PubMed]
37. Lamaze C, Dujeancourt A, Baba T, Lo CG, Benmerah A, Dautry-Varsat A. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell. 2001;7(3):661–671. [PubMed]
38. Grassart A, Dujeancourt A, Lazarow PB, Dautry-Varsat A, Sauvonnet N. Clathrin-independent endocytosis used by the IL-2 receptor is regulated by Rac1, Pak1 and Pak2. EMBO Rep. 2008;9(4):356–362. [PubMed]
39. Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat Cell Biol. 2006;8(1):46–54. [PubMed]
40. Nichols BJ, Kenworthy AK, Polishchuk RS, Lodge R, Roberts TH, Hirschberg K, Phair RD, Lippincott-Schwartz J. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J Cell Biol. 2001;153(3):529–541. [PMC free article] [PubMed]
41. Putnam MA, Moquin AE, Merrihew M, Outcalt C, Sorge E, Caballero A, Gondre-Lewis TA, Drake JR. Lipid raft-independent B cell receptor-mediated antigen internalization and intracellular trafficking. J Immunol. 2003;170(2):905–912. [PubMed]
42. Santini F, Keen JH. Endocytosis of activated receptors and clathrin-coated pit formation: deciphering the chicken or egg relationship. J Cell Biol. 1996;132(6):1025–1036. [PMC free article] [PubMed]
43. Finger EC, Lee NY, You HJ, Blobe GC. Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J Biol Chem. 2008;283(50):34808–34818. [PubMed]
44. Roallason R, Korolchuk V, Hamilton C, Schu P, Banting G. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci. 2007;120(Pt 21):3850–3858. [PubMed]
45. Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem. 2003;72:395–447. [PubMed]
46. Hou P, Araujo E, Zhao T, Zhang M, Massenburg D, Veselits M, Doyle C, Dinner AR, Clark MR. B Cell Antigen Receptor Signaling and Internalization Are Mutually Exclusive Events. PLoS Biol. 2006;4(7):e200. [PMC free article] [PubMed]
47. Henley JR, Krueger EW, Oswald BJ, McNiven MA. Dynamin-mediated internalization of caveolae. J Cell Biol. 1998;141(1):85–99. [PMC free article] [PubMed]
48. Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol. 2004;5(2):133–147. [PubMed]
49. Mears JA, Hinshaw JE. Visualization of dynamins. Methods Cell Biol. 2008;88:237–256. [PMC free article] [PubMed]
50. Marks B, Stowell MH, Vallis Y, Mills IG, Gibson A, Hopkins CR, McMahon HT. GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature. 2001;410(6825):231–235. [PubMed]
51. Damke H, Baba T, Warnock DE, Schmid SL. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol. 1994;127(4):915–934. [PMC free article] [PubMed]
52. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006;10(6):839–850. [PubMed]
53. D’Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol. 2006;7(5):347–358. [PubMed]
54. Donaldson JG. Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. J Biol Chem. 2003;278(43):41573–41576. [PubMed]
55. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K–regulated ARF6 endocytic pathway. Cell. 2002;111(6):853–866. [PubMed]
56. Naslavsky N, Weigert R, Donaldson JG. Convergence of non-clathrin- and clathrin-derived endosomes involves Arf6 inactivation and changes in phosphoinositides. Mol Biol Cell. 2003;14(2):417–431. [PMC free article] [PubMed]
57. Radhakrishna H, Donaldson JG. ADP-ribosylation factor 6 regulates a novel plasma membrane recycling pathway. J Cell Biol. 1997;139(1):49–61. [PMC free article] [PubMed]
58. Brown FD, Rozelle AL, Yin HL, Balla T, Donaldson JG. Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated membrane traffic. J Cell Biol. 2001;154(5):1007–1017. [PMC free article] [PubMed]
59. Swanson JA, Watts C. Macropinocytosis. Trends Cell Biol. 1995;5(11):424–428. [PubMed]
60. Amyere M, Mettlen M, Van Der Smissen P, Platek A, Payrastre B, Veithen A, Courtoy PJ. Origin, originality, functions, subversions and molecular signalling of macropinocytosis. Int J Med Microbiol. 2002;291(6–7):487–494. [PubMed]
61. Nichols BJ, Lippincott-Schwartz J. Endocytosis without clathrin coats. Trends Cell Biol. 2001;11(10):406–412. [PubMed]
62. Kerr MC, Teasdale RD. Defining macropinocytosis. Traffic. 2009;10(4):364–371. [PubMed]
63. von Delwig A, Hilkens CM, Altmann DM, Holmdahl R, Isaacs JD, Harding CV, Robertson H, McKie N, Robinson JH. Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. Arthritis Res Ther. 2006;8(4):R93. [PMC free article] [PubMed]
64. Engqvist-Goldstein AE, Drubin DG. Actin assembly and endocytosis: from yeast to mammals. Annu Rev Cell Dev Biol. 2003;19:287–332. [PubMed]
65. West MA, Prescott AR, Eskelinen EL, Ridley AJ, Watts C. Rac is required for constitutive macropinocytosis by dendritic cells but does not control its downregulation. Curr Biol. 2000;10(14):839–848. [PubMed]
66. Garrett WS, Chen LM, Kroschewski R, Ebersold M, Turley S, Trombetta S, Galan JE, Mellman I. Developmental control of endocytosis in dendritic cells by Cdc42. Cell. 2000;102(3):325–334. [PubMed]
67. Keller HU. Diacylglycerols and PMA are particularly effective stimulators of fluid pinocytosis in human neutrophils. J Cell Physiol. 1990;145(3):465–471. [PubMed]
68. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70(3):401–410. [PubMed]
69. Dharmawardhane S, Schurmann A, Sells MA, Chernoff J, Schmid SL, Bokoch GM. Regulation of macropinocytosis by p21-activated kinase-1. Mol Biol Cell. 2000;11(10):3341–3352. [PMC free article] [PubMed]
70. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, Koval M. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci. 2003;116(Pt 8):1599–1609. [PubMed]
71. Wienke DC, Knetsch ML, Neuhaus EM, Reedy MC, Manstein DJ. Disruption of a dynamin homologue affects endocytosis, organelle morphology, and cytokinesis in Dictyostelium discoideum. Mol Biol Cell. 1999;10(1):225–243. [PMC free article] [PubMed]
72. Amyere M, Payrastre B, Krause U, Van Der Smissen P, Veithen A, Courtoy PJ. Constitutive macropinocytosis in oncogene-transformed fibroblasts depends on sequential permanent activation of phosphoinositide 3-kinase and phospholipase C. Mol Biol Cell. 2000;11(10):3453–3467. [PMC free article] [PubMed]
73. Schafer DA, D’Souza-Schorey C, Cooper JA. Actin assembly at membranes controlled by ARF6. Traffic. 2000;1(11):892–903. [PubMed]
74. Nobes C, Marsh M. Dendritic cells: new roles for Cdc42 and Rac in antigen uptake? Curr Biol. 2000;10(20):R739–R741. [PubMed]
75. Norbury CC. Drinking a lot is good for dendritic cells. Immunology. 2006;117(4):443–451. [PubMed]
76. Falcone S, Cocucci E, Podini P, Kirchhausen T, Clementi E, Meldolesi J. Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J Cell Sci. 2006;119(Pt 22):4758–4769. [PubMed]
77. de Baey A, Lanzavecchia A. The role of aquaporins in dendritic cell macropinocytosis. J Exp Med. 2000;191(4):743–748. [PMC free article] [PubMed]
78. Mettlen M, Platek A, Van Der Smissen P, Carpentier S, Amyere M, Lanzetti L, de Diesbach P, Tyteca D, Courtoy PJ. Src triggers circular ruffling and macropinocytosis at the apical surface of polarized MDCK cells. Traffic. 2006;7(5):589–603. [PubMed]
79. Araki N, Johnson MT, Swanson JA. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J Cell Biol. 1996;135(5):1249–1260. [PMC free article] [PubMed]
80. Cao H, Chen J, Awoniyi M, Henley JR, McNiven MA. Dynamin 2 mediates fluid-phase micropinocytosis in epithelial cells. J Cell Sci. 2007;120(Pt 23):4167–4177. [PubMed]
81. Acconcia F, Sigismund S, Polo S. Ubiquitin in trafficking: the network at work. Exp Cell Res. 2009;315(9):1610–1618. [PubMed]
82. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications. J Cell Biochem Suppl. 2000;34:40–51. [PubMed]
83. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol. 2001;2(3):169–178. [PubMed]
84. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science. 2007;315(5809):201–205. [PubMed]
85. Pickart CM, Fushman D. Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol. 2004;8(6):610–616. [PubMed]
86. Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell. 2006;21(6):737–748. [PubMed]
87. Duncan LM, Piper S, Dodd RB, Saville MK, Sanderson CM, Luzio JP, Lehner PJ. Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules. EMBO J. 2006;25(8):1635–1645. [PubMed]
88. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP, Polo S. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U S A. 2005;102(8):2760–2765. [PubMed]
89. Molfetta R, Gasparrini F, Peruzzi G, Vian L, Piccoli M, Frati L, Santoni A, Paolini R. Lipid raft-dependent FcepsilonRI ubiquitination regulates receptor endocytosis through the action of ubiquitin binding adaptors. PLoS ONE. 2009;4(5):e5604. [PMC free article] [PubMed]
90. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol. 2004;5(2):121–132. [PubMed]
91. Gruenberg J. The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol. 2001;2(10):721–730. [PubMed]
92. Zoncu R, Perera RM, Balkin DM, Pirruccello M, Toomre D, De Camilli P. A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell. 2009;136(6):1110–1121. [PMC free article] [PubMed]
93. Sonnichsen B, De Renzis S, Nielsen E, Rietdorf J, Zerial M. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J Cell Biol. 2000;149(4):901–914. [PMC free article] [PubMed]
94. Hayakawa A, Leonard D, Murphy S, Hayes S, Soto M, Fogarty K, Standley C, Bellve K, Lambright D, Mello C, Corvera S. The WD40 and FYVE domain containing protein 2 defines a class of early endosomes necessary for endocytosis. Proc Natl Acad Sci U S A. 2006;103(32):11928–11933. [PubMed]
95. Lakadamyali M, Rust MJ, Zhuang X. Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell. 2006;124(5):997–1009. [PMC free article] [PubMed]
96. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2001;2(2):107–117. [PubMed]
97. Miaczynska M, Zerial M. Mosaic organization of the endocytic pathway. Exp Cell Res. 2002;272(1):8–14. [PubMed]
98. Spang A. On the fate of early endosomes. Biol Chem. 2009 [PubMed]
99. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell. 2005;122(5):735–749. [PubMed]
100. Vonderheit A, Helenius A. Rab7 associates with early endosomes to mediate sorting and transport of Semliki forest virus to late endosomes. PLoS Biol. 2005;3(7):e233. [PMC free article] [PubMed]
101. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495–502. [PMC free article] [PubMed]
102. Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol. 2009 Chapter 14:Unit 14 10. [PubMed]
103. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, Solana R, Coligan JE. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol. 2002;38(9):637–660. [PubMed]
104. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev. 2008;224:70–84. [PMC free article] [PubMed]
105. Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 1997;7(2):283–290. [PubMed]
106. Tang X, Narayanan S, Peruzzi G, Apara A, Natarajan K, Margulies DH, Coligan JE, Borrego F. A single residue, arginine 65, is critical for the functional interaction of leukocyte-associated inhibitory receptor-1 with collagens. J Immunol. 2009;182(9):5446–5452. [PMC free article] [PubMed]
107. Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, Farndale RW, Lisman T, Sonnenberg A, Lenting PJ, Meyaard L. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med. 2006;203(6):1419–1425. [PMC free article] [PubMed]
108. Cantoni C, Bottino C, Augugliaro R, Morelli L, Marcenaro E, Castriconi R, Vitale M, Pende D, Sivori S, Millo R, Biassoni R, Moretta L, Moretta A. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol. 1999;29(10):3148–3159. [PubMed]
109. Ito M, Maruyama T, Saito N, Koganei S, Yamamoto K, Matsumoto N. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med. 2006;203(2):289–295. [PMC free article] [PubMed]
110. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159–166. [PubMed]
111. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol. 2005;174(8):4480–4484. [PubMed]
112. Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE. The NKG2D receptor: immunobiology and clinical implications. Immunol Res. 2008;40(1):18–34. [PubMed]
113. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O’Reilly RJ, Dupont B, Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol. 2003;171(12):6891–6899. [PubMed]
114. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 2003;18(1):41–51. [PubMed]
115. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–738. [PubMed]
116. Salih HR, Rammensee H-G, Steinle A. Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding. J Immunol. 2002;169(8):4098–4102. [PubMed]
117. Roda Navarro P, Reyburn HT. The traffic of the NKG2D/DAP10 receptor complex during NK cell activation. J Biol Chem. 2009 [PubMed]
118. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol. 1999;29(5):1656–1666. [PubMed]
119. Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V, Momburg F. Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J Virol. 2009 [PMC free article] [PubMed]
120. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001;409(6823):1055–1060. [PubMed]
121. Sivori S, Parolini S, Falco M, Marcenaro E, Biassoni R, Bottino C, Moretta L, Moretta A. 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol. 2000;30(3):787–793. [PubMed]
122. Sandusky MM, Messmer B, Watzl C. Regulation of 2B4 (CD244)-mediated NK cell activation by ligand-induced receptor modulation. Eur J Immunol. 2006;36(12):3268–3276. [PubMed]
123. Wang X, Ottosson A, Ji C, Feng X, Nordenskjold M, Henter JI, Fadeel B, Zheng C. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica. 2009 [PubMed]
124. Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA, Schmidt RE, Sandor M, Capel PJ, Daeron M, van de Winkel JG, Verbeek JS. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity. 1996;5(2):181–188. [PubMed]
125. Vivier E, Morin P, O’Brien C, Druker B, Schlossman SF, Anderson P. Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J Immunol. 1991;146(1):206–210. [PubMed]
126. O’Shea JJ, Weissman AM, Kennedy IC, Ortaldo JR. Engagement of the natural killer cell IgG Fc receptor results in tyrosine phosphorylation of the zeta chain. Proc Natl Acad Sci U S A. 1991;88(2):350–354. [PubMed]
127. Cecchetti S, Spadaro F, Lugini L, Podo F, Ramoni C. Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells. Eur J Immunol. 2007;37(10):2912–2922. [PubMed]
128. Borrego F, Lopez-Beltran A, Pena J, Solana R. Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. Cell Immunol. 1994;158(1):208–217. [PubMed]
129. Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II) J Immunol. 1991;147(10):3459–3465. [PubMed]
130. Paolini R, Serra A, Molfetta R, Piccoli M, Frati L, Santoni A. Tyrosine kinase-dependent ubiquitination of CD16 zeta subunit in human NK cells following receptor engagement. Eur J Immunol. 1999;29(10):3179–3187. [PubMed]
131. Morandi B, Costa R, Falco M, Parolini S, De Maria A, Ratto G, Mingari MC, Melioli G, Moretta A, Ferlazzo G. Distinctive lack of CD48 expression in subsets of human dendritic cells tunes NK cell activation. J Immunol. 2005;175(6):3690–3697. [PubMed]
132. Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, Bottino C, Moretta L, Moretta A. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci U S A. 2002;99(7):4526–4531. [PubMed]
133. Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, Bennett M, Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med. 2004;199(9):1245–1254. [PMC free article] [PubMed]
134. Bhat R, Eissmann P, Endt J, Hoffmann S, Watzl C. Fine-tuning of immune responses by SLAM-related receptors. J Leukoc Biol. 2006;79(3):417–424. [PubMed]
135. Assarsson E, Kambayashi T, Persson CM, Ljunggren HG, Chambers BJ. 2B4 co-stimulation: NK cells and their control of adaptive immune responses. Mol Immunol. 2005;42(4):419–423. [PubMed]
136. McNerney ME, Lee KM, Kumar V. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Mol Immunol. 2005;42(4):489–494. [PubMed]
137. Boles KS, Stepp SE, Bennett M, Kumar V, Mathew PA. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001;181:234–249. [PubMed]
138. Welstead GG, Hsu EC, Iorio C, Bolotin S, Richardson CD. Mechanism of CD150 (SLAM) down regulation from the host cell surface by measles virus hemagglutinin protein. J Virol. 2004;78(18):9666–9674. [PMC free article] [PubMed]
139. Del Valle JM, Engel P, Martin M. The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2) J Biol Chem. 2003;278(19):17430–17437. [PubMed]
140. Borrego F, Masilamani M, Marusina AI, Tang X, Coligan JE. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res. 2006;35(3):263–278. [PubMed]
141. Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J Exp Med. 1997;185(4):795–800. [PMC free article] [PubMed]
142. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187(5):813–818. [PMC free article] [PubMed]
143. Carretero M, Palmieri G, Llano M, Tullio V, Santoni A, Geraghty DE, Lopez-Botet M. Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants. Eur J Immunol. 1998;28(4):1280–1291. [PubMed]
144. Kabat J, Borrego F, Brooks A, Coligan JE. Role that each NKG2A immunoreceptor tyrosine-based inhibitory motif plays in mediating the human CD94/NKG2A inhibitory signal. J Immunol. 2002;169(4):1948–1958. [PubMed]
145. Le Drean E, Vely F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol. 1998;28(1):264–276. [PubMed]
146. Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE. The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol. 2005;42(4):485–488. [PubMed]
147. Masilamani M, Nguyen C, Kabat J, Borrego F, Coligan JE. CD94/NKG2A Inhibits NK Cell Activation by Disrupting the Actin Network at the Immunological Synapse. J Immunol. 2006;177(6):3590–3596. [PubMed]
148. Sanni TB, Masilamani M, Kabat J, Coligan JE, Borrego F. Exclusion of lipid rafts and decreased mobility of CD94/NKG2A receptors at the inhibitory NK cell synapse. Mol Biol Cell. 2004;15(7):3210–3223. [PMC free article] [PubMed]
149. Borrego F, Kabat J, Sanni TB, Coligan JE. NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes. J Immunol. 2002;169(11):6102–6111. [PubMed]
150. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 1998;8(6):693–701. [PubMed]
151. Wood SA, Park JE, Brown WJ. Brefeldin A causes a microtubule-mediated fusion of the trans-Golgi network and early endosomes. Cell. 1991;67(3):591–600. [PubMed]
152. Lippincott-Schwartz J, Yuan L, Tipper C, Amherdt M, Orci L, Klausner RD. Brefeldin A’s effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell. 1991;67(3):601–616. [PubMed]
153. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol. 2004;16(5):626–633. [PubMed]
154. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391(6668):703–707. [PubMed]
155. Kikuchi-Maki A, Yusa S, Catina TL, Campbell KS. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol. 2003;171(7):3415–3425. [PubMed]
156. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, Long EO. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 2006;4(1):e9. [PMC free article] [PubMed]
157. Rajagopalan S, Fu J, Long EO. Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol. 2001;167(4):1877–1881. [PubMed]
158. Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein. J Immunol. 2005;174(7):3859–3863. [PubMed]
159. Miah SM, Hughes TL, Campbell KS. KIR2DL4 differentially signals downstream functions in human NK cells through distinct structural modules. J Immunol. 2008;180(5):2922–2932. [PubMed]
160. Huard B, Karlsson L. KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature. 2000;403(6767):325–328. [PubMed]
161. Huard B, Karlsson L, Triebel F. KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation. Eur J Immunol. 2001;31(6):1728–1735. [PubMed]
162. Chwae YJ, Lee JM, Kim EJ, Lee ST, Soh JW, Kim J. Activation-induced upregulation of inhibitory killer Ig-like receptors is regulated by protein kinase C. Immunol Cell Biol. 2007;85(3):220–228. [PubMed]
163. Chwae YJ, Lee JM, Kim HR, Kim EJ, Lee ST, Soh JW, Kim J. Amino-acid sequence motifs for PKC-mediated membrane trafficking of the inhibitory killer Ig-like receptor. Immunol Cell Biol. 2008;86(4):372–380. [PubMed]
164. Alvarez-Arias DA, Campbell KS. Protein kinase C regulates expression and function of inhibitory killer cell Ig-like receptors in NK cells. J Immunol. 2007;179(8):5281–5290. [PubMed]
165. van der Meer A, Lukassen HG, van Lierop MJ, Wijnands F, Mosselman S, Braat DD, Joosten I. Membrane-bound HLA-G activates proliferation and interferon-gamma production by uterine natural killer cells. Mol Hum Reprod. 2004;10(3):189–195. [PubMed]
166. Ortaldo JR, Mason AT, O’Shea JJ. Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med. 1995;181(1):339–344. [PMC free article] [PubMed]
167. Poggi A, Massaro AM, Negrini S, Contini P, Zocchi MR. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol. 2005;174(5):2653–2660. [PubMed]
168. Lou Z, Jevremovic D, Billadeau DD, Leibson PJ. A balance between positive and negative signals in cytotoxic lymphocytes regulates the polarization of lipid rafts during the development of cell-mediated killing. J Exp Med. 2000;191(2):347–354. [PMC free article] [PubMed]
169. Watzl C, Long EO. Natural killer cell inhibitory receptors block actin cytoskeleton-dependent recruitment of 2B4 (CD244) to lipid rafts. J Exp Med. 2003;197(1):77–85. [PMC free article] [PubMed]
170. Krzewski K, Chen X, Orange JS, Strominger JL. Formation of a WIP-, WASp-, actin-, and myosin IIA-containing multiprotein complex in activated NK cells and its alteration by KIR inhibitory signaling. J Cell Biol. 2006;173(1):121–132. [PMC free article] [PubMed]
171. May RC, Machesky LM. Phagocytosis and the actin cytoskeleton. J Cell Sci. 2001;114(Pt 6):1061–1077. [PubMed]
172. Welch MD, Mullins RD. Cellular control of actin nucleation. Annu Rev Cell Dev Biol. 2002;18:247–288. [PubMed]
173. Stebbins CC, Watzl C, Billadeau DD, Leibson PJ, Burshtyn DN, Long EO. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol. 2003;23(17):6291–6299. [PMC free article] [PubMed]